ENANTA PHARMACEUTICALS, INC Defined Contribution Plan, Cost
ENANTA PHARMACEUTICALS, INC (ENTA) reported Defined Contribution Plan, Cost of $1.68 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC defined contribution plan, cost for fiscal 2025 was $1.68M, a 0.77% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC defined contribution plan, cost for fiscal 2024 was $1.70M, a 4.88% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC defined contribution plan, cost for fiscal 2023 was $1.78M, a 11.78% increase from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC defined contribution plan, cost for fiscal 2022 was $1.60M, a 17.96% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-09-30 | $1.68M 10-K · filed 2025-11-19 |
| 2024-09-30 | $1.70M 10-K · filed 2025-11-19 |
| 2023-09-30 | $1.78M 10-K · filed 2025-11-19 |
| 2022-09-30 | $1.60M 10-K · filed 2024-11-27 |
| 2021-09-30 | $1.35M 10-K · filed 2023-11-22 |
| 2020-09-30 | $1.19M 10-K · filed 2022-11-23 |
| 2019-09-30 | $1.07M 10-K · filed 2021-11-24 |
| 2018-09-30 | $852.00K 10-K · filed 2020-11-25 |
| 2017-09-30 | $712.00K 10-K · filed 2019-11-27 |
| 2016-09-30 | $513.00K 10-K · filed 2018-11-29 |
| 2015-09-30 | $382.00K 10-K · filed 2017-12-11 |
| 2014-09-30 | $180.00K 10-K · filed 2016-12-09 |
| 2013-09-30 | $90.00K 10-K · filed 2015-12-11 |
| 2012-09-30 | $84.00K 10-K · filed 2014-12-11 |
| 2011-09-30 | $95.00K 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |